The Change and Significance of Serum Ghrelin and Visfatin after Roux-en-Y Gastric Bypass Surgery in Treatment of Type-2 Diabetes Mellitus Rats_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 YINYan-bin ,  WANGYue-sheng , ZHANGLi-hai , SUDe-wang

Department of The First General Surgery, The First Affiliated Hospital of Jiamusi University, Jiamusi 154003, Heilongjiang Province, China;

Corresponding author：

WANGYue-sheng, Email: wys9906@163.com

Keywords：

Type-2 diabetes mellitus; Roux-en-Y gastric bypass surgery; Ghrelin; Visfatin; Rat

DOI：

10.7507/1007-9424.20160365

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To research the change and significance of Ghrelin and Visfatin in plasma after Roux-en-Y gastric bypass surgery (RYGB) in type-2 diabetes (T2DM) rats. Methods Thirty healthy Sprague Dawley (SD) rats (8 weeks) were divided into T2DM group (n=22) and blank control group (CSO group, n=8). Then rats of T2DM group were fed with high calorie and high sugar diet for 6 weeks, following by one dose of streptozotocin via intraperitioneal injection. Finally, there were 18 T2DM rats were successfully established. Then those 18 T2DM rats were divided into two groups:RYGB group (n=10) and sham operation group (DSO group, n=8). Rats of RYGB underwent RYGB, rats of DSO group and CSO group underwent sham operation. Levels of fasting serum glucose (FBG), fasting serum insulin (FINS), Ghrelin, and Visfatin of rats in 3 groups were detected by enzyme-linked immunoassay (EIA) before and 4 weeks after operation, and calculating the lee index and insulin sensitivity index (ISI). Results In RYGB group, compared with before operation, the body weight, lee index, levels of FBG, FINS, and Visfatin decreased after 4 weeks after operation (P < 0.050), but level of ISI and Ghrelin increased (P < 0.050), while there was no significant difference in body weight, body length, lee index, ISI, levels of FBG, FINS, Ghrelin, and Visfatin in DSO and CSO group before and 4 weeks after operation (P > 0.050). In addition, there was statistical difference among the 3 groups in difference before and after operation of Ghrelin and Visfatin, the difference before and after operation of Ghrelin and Visfatin was larger than those of DSO group and CSO group (P < 0.050), but the difference was not significant differed between DSO group and CSO group (P > 0.050). Conclusions The increase of plasma Ghrelin and the decrease of Visfatin play important role in the mechanism after RYGB in treatment of T2DM rats.

Citation： YINYan-bin, WANGYue-sheng, ZHANGLi-hai, SUDe-wang. The Change and Significance of Serum Ghrelin and Visfatin after Roux-en-Y Gastric Bypass Surgery in Treatment of Type-2 Diabetes Mellitus Rats. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2016, 23(12): 1432-1436. doi: 10.7507/1007-9424.20160365 Copy

1.	Dogan K, Betzel B, Homan J, et al. Long-term effects of laparoscopic Roux-en-Y gastric bypass on diabetes mellitus, hypertension and dyslipidaemia in morbidly obese patients. Obes Surg, 2014, 24(11):1835-1842.
2.	Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med, 2012, 366(17):1577-1585.
3.	张玉领, 孙长颢. Ⅱ型糖尿病动物模型的研究进展.现代预防医学, 2012, 39(8):2015-2017.
4.	Baker S, Jerums G, Proietto J. Effects and clinical potential of very-low-calorie diets (VLCDs) in type 2 diabetes. Diabtes Res Clin Pract, 2009, 85(3):235-242.
5.	Bueter M, Abegg K, Seyfried F, et al. Roux-en-Y gastric bypass operation in rats. J Vis Exp, 2012, 64(64):e3940.
6.	张立海, 夏宾, 王娇, 等. Roux-en-Y胃旁路术对2型糖尿病大鼠炎症因子及脂肪组织胰岛素受体底物-1/2表达影响的实验研究.中国普外基础与临床杂志, 2015, 22(12):1460-1465.
7.	文艺, 祁巧, 刘丹青. Roux-en-Y胃旁路术对2型糖尿病大鼠肾脏早期损害的保护作用.中国普外基础与临床杂志, 2015, 22(4):408-411.
8.	Simianu VV, Sham JG, Wright AS, et al. A large animal survival model to evaluate bariatric surgery mechanisms. Surg Sci, 2015, 6(8):337-345.
9.	Pattou F, Daoudi M, Baud G. Roux-en-Y gastric bypass and intestinal glucose handling:a salty sweet operation. Gastroenterology, 2016, 151(1):210.
10.	朱姿英, 薛耀明.高甘油三酯血症和2型糖尿病.中国糖尿病杂志, 2003, 11(2):153-154.
11.	王跃生, 史逸华, 陈福军.胃转流术对2型糖尿病大鼠空腹血糖的影响及其机理.中国普外基础与临床杂志, 2011, 18(8):849-853.
12.	张晓娟, 杜涓, 杜潇, 等.腹腔镜下胃转流术治疗肥胖型2型糖尿病的疗效分析.中国普外基础与临床杂志, 2012, 19(12):1272-1277.
13.	沈宏, 赵冬雨, 张宁.胃转流术治疗2型糖尿病的疗效及影响疗效的相关因素.中国普外基础与临床杂志, 2014, 21(2):223-225.
14.	Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature, 1999, 402(6762):656-660.
15.	Lappas M, Jinks D, Ugoni A, et al. Post-partum plasma C-peptide and ghrelin concentrations are predictive of type 2 diabetes in women with previous gestational diabetes mellitus. J Diabetes, 2015, 7(4):506-511.
16.	Müller TD, Nogueiras R, Andermann ML, et al. Ghrelin. Mol Metab, 2015, 4(6):437-460.
17.	Kadoglou NP, Fotiadis G, Kapelouzou A, et al. The differential anti-inflammatory effects of exercise modalities and their association with early carotid atherosclerosis progression in patients with type 2 diabetes. Diabet Med, 2013, 30(2):e41-e50.
18.	Kadoglou NP, Sailer N, Kapelouzou A, et al. Effects of atorvastatin on apelin, visfatin (nampt), ghrelin and early carotid atherosclerosis in patients with type 2 diabetes. Acta Diabetol, 2012, 49(4):269-276.
19.	Kim DS, Kang S, Moon NR, et al. Central visfatin potentiates glucose-stimulated insulin secretion and β-cell mass without increasing serum visfatin levels in diabetic rats. Cytokine, 2014, 65(2):159-166.
20.	Cavin JB, Couvelard A, Lebtahi R, et al. Differences in alimentary glucose absorption and intestinal disposal of blood glucose after Roux-en-Y gastric bypass vs sleeve gastrectomy. Gastroenterology, 2016, 150(2):454-464.
21.	Nergård BJ, Lindqvist A, Gislason HG, et al. Mucosal glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide cell numbers in the super-obese human foregut after gastric bypass. Surg Obes Relat Dis, 2015, 11(6):1237-1246.
22.	Nass RM, Gaylinn BD, Rogol AD, et al. Ghrelin and growth hormone:story in reverse. Proc Natl Acad Sci U S A, 2010, 107(19):8501-8502.
23.	Gagnon J, Baggio LL, Drucker DJ. Ghrelin is a novel regulator of GLP-1 secretion. Diabetes, 2015, 64(5):1513-1521.
24.	Esteghamati A, Alamdari A, Zandieh A, et al. Serum visfatin is associated with type 2 diabetes mellitus independent of insulin resistance and obesity. Diabetes Res Clin Pract, 2011, 91(2):154-158.
25.	Saboori S, Hosseinzadeh-Attar MJ, Yousefi RE, et al. The comparison of serum vaspin and visfatin concentrations in obese and normal weight women. Diabetes Metab Syndr, 2015, 9(4):320-323.
26.	Ahmed MB, Ismail MI, Meki AR. Relation of Osteoprotegerin, Visfatin and Ghrelin to metabolic syndrome in type 2 diabetic patients. Int J Health Sci (Qassim), 2015, 9(2):127-139.
27.	Salemi Z, Rafie E, Goodarzi MT, et al. Effect of metformin, acarbose and their combination on the serum visfatin level in nicotinamide/streptozocin-induced type 2 diabetic rats. Iran Red Crescent Med J, 2016, 18(3):e23814.
28.	Asadi S, Goodarzi MT, Saidijam M, et al. Resveratrol attenuates visfatin and vaspin genes expression in adipose tissue of rats with type 2 diabetes. Iran J Basic Med Sci, 2015, 18(6):537-543.

1. Dogan K, Betzel B, Homan J, et al. Long-term effects of laparoscopic Roux-en-Y gastric bypass on diabetes mellitus, hypertension and dyslipidaemia in morbidly obese patients. Obes Surg, 2014, 24(11):1835-1842.
2. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med, 2012, 366(17):1577-1585.
3. 张玉领, 孙长颢. Ⅱ型糖尿病动物模型的研究进展.现代预防医学, 2012, 39(8):2015-2017.
4. Baker S, Jerums G, Proietto J. Effects and clinical potential of very-low-calorie diets (VLCDs) in type 2 diabetes. Diabtes Res Clin Pract, 2009, 85(3):235-242.
5. Bueter M, Abegg K, Seyfried F, et al. Roux-en-Y gastric bypass operation in rats. J Vis Exp, 2012, 64(64):e3940.
6. 张立海, 夏宾, 王娇, 等. Roux-en-Y胃旁路术对2型糖尿病大鼠炎症因子及脂肪组织胰岛素受体底物-1/2表达影响的实验研究.中国普外基础与临床杂志, 2015, 22(12):1460-1465.
7. 文艺, 祁巧, 刘丹青. Roux-en-Y胃旁路术对2型糖尿病大鼠肾脏早期损害的保护作用.中国普外基础与临床杂志, 2015, 22(4):408-411.
8. Simianu VV, Sham JG, Wright AS, et al. A large animal survival model to evaluate bariatric surgery mechanisms. Surg Sci, 2015, 6(8):337-345.
9. Pattou F, Daoudi M, Baud G. Roux-en-Y gastric bypass and intestinal glucose handling:a salty sweet operation. Gastroenterology, 2016, 151(1):210.
10. 朱姿英, 薛耀明.高甘油三酯血症和2型糖尿病.中国糖尿病杂志, 2003, 11(2):153-154.
11. 王跃生, 史逸华, 陈福军.胃转流术对2型糖尿病大鼠空腹血糖的影响及其机理.中国普外基础与临床杂志, 2011, 18(8):849-853.
12. 张晓娟, 杜涓, 杜潇, 等.腹腔镜下胃转流术治疗肥胖型2型糖尿病的疗效分析.中国普外基础与临床杂志, 2012, 19(12):1272-1277.
13. 沈宏, 赵冬雨, 张宁.胃转流术治疗2型糖尿病的疗效及影响疗效的相关因素.中国普外基础与临床杂志, 2014, 21(2):223-225.
14. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature, 1999, 402(6762):656-660.
15. Lappas M, Jinks D, Ugoni A, et al. Post-partum plasma C-peptide and ghrelin concentrations are predictive of type 2 diabetes in women with previous gestational diabetes mellitus. J Diabetes, 2015, 7(4):506-511.
16. Müller TD, Nogueiras R, Andermann ML, et al. Ghrelin. Mol Metab, 2015, 4(6):437-460.
17. Kadoglou NP, Fotiadis G, Kapelouzou A, et al. The differential anti-inflammatory effects of exercise modalities and their association with early carotid atherosclerosis progression in patients with type 2 diabetes. Diabet Med, 2013, 30(2):e41-e50.
18. Kadoglou NP, Sailer N, Kapelouzou A, et al. Effects of atorvastatin on apelin, visfatin (nampt), ghrelin and early carotid atherosclerosis in patients with type 2 diabetes. Acta Diabetol, 2012, 49(4):269-276.
19. Kim DS, Kang S, Moon NR, et al. Central visfatin potentiates glucose-stimulated insulin secretion and β-cell mass without increasing serum visfatin levels in diabetic rats. Cytokine, 2014, 65(2):159-166.
20. Cavin JB, Couvelard A, Lebtahi R, et al. Differences in alimentary glucose absorption and intestinal disposal of blood glucose after Roux-en-Y gastric bypass vs sleeve gastrectomy. Gastroenterology, 2016, 150(2):454-464.
21. Nergård BJ, Lindqvist A, Gislason HG, et al. Mucosal glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide cell numbers in the super-obese human foregut after gastric bypass. Surg Obes Relat Dis, 2015, 11(6):1237-1246.
22. Nass RM, Gaylinn BD, Rogol AD, et al. Ghrelin and growth hormone:story in reverse. Proc Natl Acad Sci U S A, 2010, 107(19):8501-8502.
23. Gagnon J, Baggio LL, Drucker DJ. Ghrelin is a novel regulator of GLP-1 secretion. Diabetes, 2015, 64(5):1513-1521.
24. Esteghamati A, Alamdari A, Zandieh A, et al. Serum visfatin is associated with type 2 diabetes mellitus independent of insulin resistance and obesity. Diabetes Res Clin Pract, 2011, 91(2):154-158.
25. Saboori S, Hosseinzadeh-Attar MJ, Yousefi RE, et al. The comparison of serum vaspin and visfatin concentrations in obese and normal weight women. Diabetes Metab Syndr, 2015, 9(4):320-323.
26. Ahmed MB, Ismail MI, Meki AR. Relation of Osteoprotegerin, Visfatin and Ghrelin to metabolic syndrome in type 2 diabetic patients. Int J Health Sci (Qassim), 2015, 9(2):127-139.
27. Salemi Z, Rafie E, Goodarzi MT, et al. Effect of metformin, acarbose and their combination on the serum visfatin level in nicotinamide/streptozocin-induced type 2 diabetic rats. Iran Red Crescent Med J, 2016, 18(3):e23814.
28. Asadi S, Goodarzi MT, Saidijam M, et al. Resveratrol attenuates visfatin and vaspin genes expression in adipose tissue of rats with type 2 diabetes. Iran J Basic Med Sci, 2015, 18(6):537-543.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

The Change and Significance of Serum Ghrelin and Visfatin after Roux-en-Y Gastric Bypass Surgery in Treatment of Type-2 Diabetes Mellitus Rats

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content